Emcure Launches OTC Portfolio of Galact for New Mothers

Emcure Launches OTC Portfolio of Galact for New Mothers

By, Admin 13 March 2024

Emcure Pharma launches OTC portfolio with Galact supplement for breastfeeding mothers

Overview

Emcure Pharmaceuticals, an Indian pharmaceutical company with a strong focus on women’s healthcare, announces its entry into the over-the-counter (OTC) market, with their product Galact. Prescribed by healthcare professionals for more than 20 years, Galact will now also be available as an over-the-counter (OTC) offering.

Galact Ingredients & Positive Effects 

  • Enriched with the potency of Shatavari and six other herbs, Galact is meticulously formulated to boost breast milk production for mothers. Shatavari is also known to enhance baby’s weight, sleep pattern, leading to better immunity. 
  • While a key ingredient, Yashtimadhu, helps in enhancing cognitive function, memory, and concentration, thereby assisting in improving baby’s IQ. 
  • Following the launch of Galact, Emcure will be able to introduce a diverse array of OTC products catering to the unique needs of women.

Words from Director: Emcure 

Speaking on the occasion, Namita Thapar, whole-time director, Emcure Pharmaceuticals said, “Emcure has always focused on awareness, access, and affordability to strengthen women’s health in India. The launch of Galact marks our efforts to redefine and further elevate the standard of women’s health solutions. Our foray into the OTC segment focuses on empowering women across various life stages, starting with a portfolio tailored for their lactation journey. In India, only 64% of mothers breastfeed their babies exclusively in the first 6 months. By making Galact available over the counter, Emcure aims to sensitise all mothers to practice exclusive breastfeeding for the first 6 months in line with the WHO and UNICEF breastfeeding guidelines. Emcure plans to introduce more products under the Galact brand.” 

Aims for Emcure

The company has a deep ethos of generating awareness around women’s health issues like anaemia, menstruation, and breastfeeding. With the launch of its renewed and redesigned Galact brand, Emcure aims to further the cause of breastfeeding and promote optimal nutrition for infants. 

Other Proposals

  • Emcure Pharmaceuticals is proposing, subject to receipt of requisite approvals, market conditions and other considerations, an initial public offering of its equity shares and has filed a draft red herring prospectus dated December 16, 2023 (DRHP) with the Securities and Exchange Board of India (SEBI). 
  • The DRHP is available on the websites of the Company at www.emcure.com, SEBI at www.sebi.gov.in, the book running lead managers, Kotak Mahindra Capital Company Limited, Axis Capital Limited, Jefferies India Private Limited, and JP Morgan India Private Limited at https://investmentbank.kotak.com, www.axiscapital.co.in, www.jefferies.com and www.jpmipl.com, respectively, and the stock exchange(s) at www.nseindia.com and www.bseindia.com, respectively.

Investments

Investors should note that investment in equity shares involves a high degree of risk and for details refer to the Red Herring Prospectus, including the section titled "Risk Factors"" of the Red Herring Prospectus when available. Potential investors should not rely on the DRHP for making any investment decision." 

About Emcure Pharmaceuticals

Emcure Pharmaceuticals (EPL) is an Indian pharmaceutical company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. Established in 1981, EPL is ranked as the 13th largest pharma company in India in terms of domestic sales for MAT September 2023.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!